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Abstract 
Introduction: Twin-twin transfusion syndrome (TTTS) complicates 15% of 
monochorionic twin pregnancies, often being associated with recipient cardiac 
dysfunction. Untreated, it has a fetal mortality rate of at least 90%; although 
treatment by fetoscopic laser coagulation significantly improves prognosis. 
Measurement of recipient amniotic fluid metabolites, such as cardiac Troponin T and 
atrial natriuretic polypeptide, correlate with cardiac function in this fetus. The aim of 
this study is to describe the amniotic fluid metabolomic profile in TTTS, relate this to 
fetal recipient cardiac function and assess the metabolomic changes induced by 
fetoscopic laser coagulation.  
Methods: Prospective single centre cohort study. The metabolomics profile of the 
amniotic fluid from the recipient sac of TTTS pregnancies was assessed using ultra 
high performance liquid chromatography-mass spectrometry. Profiles were 
compared pre- and post-laser coagulation and related to fetal recipient cardiac 
function, as assessed using Doppler ultrasound within 6 hours of treatment. 
RESULTS: Eleven metabolites had significant associations with recipient fetal right 
and left ventricular myocardial performance index pre-laser. 200 metabolites in 
recipient amniotic fluid demonstrated a change in relative concentrations when 
comparing pre- and post-laser coagulation (p<0.005). The most prominent change is 
in the balance of carbohydrate and fatty acid metabolic profile contributing to fetal or 
placental energy metabolism. These changes were also associated with the 
echocardiographic measures of recipient cardiac function.  
Discussion: Changes in carbohydrate and fatty acid metabolic profiles are noted in 
recipients with cardiac dysfunction, and further changes are noted after treatment. 
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Validation and investigation may identify targets for potential pharmacological 
treatment. 
Key words: Echocardiography, fetoscopy, laser coagulation, metabolomics, 
monochorionic twins, twin-twin transfusion syndrome 
 
Abbreviations:  
ANF – atrial natriuretic factor 
AVA – arteriovenous anastomoses 
BNP – brain-type natriuretic factor 
DV – ductus venosus 
E/A – early passive/atrial 
FLC- fetoscopic laser coagulation 
IUGR – intrauterine growth restriction 
LV – left ventricle 
MCDA – monochorionic diamniotic  
MPI – myocardial performance index 
QC – quality control 
RV – right ventricle 
TTTS – twin-twin transfusion syndrome 
UHPLC-MS - Ultra High Performance Liquid Chromatography-Mass Spectrometry 
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Introduction 1 
Approximately 15% of monochorionic dichorionic (MCDA) twins are complicated by 2 
twin-twin transfusion syndrome (TTTS), a condition associated with unidirectional intertwin 3 
blood flow through placental arteriovenous anastomoses (AVA) and high perinatal mortality. 4 
This leads to the severe haemodynamic imbalances seen within the fetal circulations of this 5 
condition with a hypertensive circulation in the “recipient” twin and subsequent cardiac 6 
dysfunction (1), noted in up to 70% of pregnancies. There is corresponding dysregulation of 7 
fetal endocrine systems, including the renin-angiotensin-aldosterone (2), atrial natriuretic 8 
factor (ANF) (3) and Endothelin-1 systems (4). Such changes have been measured in the 9 
amniotic fluid of the recipient twin, and related to cardiac dysfunction and overall fetal 10 
prognosis (3).  11 
 Untreated, fetal mortality is at least 90%, for each fetus (5). Treatment by fetoscopic 12 
laser coagulation (FLC) is effective with survival of two babies approaching 60% (6). FLC 13 
also reduces the risk of neurodevelopmental morbidity compared to other treatments (7). 14 
Improvement in recipient cardiac function is noted within 48 hours of FLC in approximately 15 
half of recipients (8), which is associated with improved fetal outcome (9). 16 
Metabolomics is the holistic untargeted study of metabolism (10) and investigates the 17 
final downstream product of genotype-environment interactions. It provides the identification 18 
of a dynamic and sensitive phenotypic signature associated with human health ageing and 19 
disease molecular pathophysiology (10). In human pregnancy, this technique has been 20 
used to investigate intrauterine growth restriction (IUGR) (11-14), pre-eclampsia (15-17) 21 
and gestational diabetes (18, 19). In non-pregnant adults, it has been used to profile 22 
functional and metabolic changes associated with heart failure (20, 21).  23 
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In MCDA pregnancies affected by TTTS, a small number of studies, targeting 24 
specific areas of metabolism have been reported (22, 23). Molecular patho-mechanistic 25 
changes have been observed in angiogenic growth factors (24), cytokine levels (25) and 26 
gene transcripts in amniotic fluid and maternal plasma which appear to predict fetal 27 
outcome (26, 27). 28 
 We describe the metabolomic profiles in amniotic fluid from the recipient sac of 29 
MCDA twin pregnancies complicated by severe TTTS and note associations between fetal 30 
echocardiographic recipient right ventricular (RV) and left ventricular (LV) function. In 31 
addition, the effects of FLC on the metabolomic profile signatures are described.  32 
Methods 33 
This study had ethical approval from Birmingham Black Country Local Research Ethics 34 
Committee (No: 06/Q2702/71 accepted in 2006) with written consent obtained from all 35 
subjects. 36 
Patient selection  37 
The cohort consisted of MCDA twins complicated by severe TTTS (presenting before 24 38 
weeks) treated between August 2011 – June 2012 and TTTS was defined as 39 
polyhydramnios (>8cm in the deepest vertical pocket of the recipient at <20 weeks of 40 
gestation or >10cm from 20 weeks of gestation onwards) in combination with 41 
oligohydramnios in the donor (<2cm deepest vertical pool depth). All cases were 42 
prospectively staged using the Quintero system (28).  43 
Cardiac function assessment 44 
High-resolution fetal ultrasound and echocardiography were performed in the recipient with 45 
curvilinear array transducers (7–3.5 MHz) on a Siemens S3000 ultrasound machine 46 
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(Siemens Ltd, Erlangan, Germany) by a single operator (MDK) and the myocardial 47 
performance index (MPI) calculated for each ventricle (1, 29) as previously described. 48 
Cardiac dysfunction was indicated by the presence of tricuspid regurgitation, reversed flow 49 
in the DV during atrial contraction, and a tricuspid early passive/atrial contraction (E/A) ratio 50 
of >95% CI outside the normal limits. This was performed within 4 hours of starting the laser 51 
procedure and repeated with 6 hours post-FLC. 52 
Fetal cardiac function was assessed 24 hours prior to FLC and repeated within 4 hours 53 
post-FLC. 54 
Fetoscopic laser coagulation (FLC) 55 
FLC was performed using local anaesthesia (1% lignocaine skin/myometrial infiltration) and 56 
maternal Remifentanil sedation as previously described (30). A selective sequential FLC 57 
technique was used, with an additional “Solomon” procedure in some cases (31). No 58 
amnio-infusion was performed.  59 
Non-targeted UHPLC-MS metabolomics analysis 60 
All solvents and chemicals applied were of HPLC analytical grade (J.T. Baker, U.K.). 61 
Sample collection and preparation. A 10ml sample of amniotic fluid was taken at 62 
insertion of the fetoscope into the recipient amniotic sac and then a further 10ml sample 63 
withdrawn at the end of the laser coagulation treatment. The median duration of the laser 64 
procedure and amniodrainage the median duration was 34 (range 21 - 45) minutes. 65 
Samples were stored at -80°C before preparation and  analysis. All samples were 66 
randomised to ensure no correlation between order of preparation and subject, disease 67 
grade or date of sample collection. Deproteinisation was performed as described below. 68 
250µL of amniotic fluid was vortex-mixed with 1000µL of methanol for 15 seconds to 69 
precipitate proteins and DNA followed by centrifugation (15 minutes, 13,000 g) drying to 70 
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induce metabolite stability and then stored at -80°C prior to analysis. A pooled quality 71 
control (QC) sample was prepared by combining 80µL aliquots of each of the 38 samples 72 
(32). 73 
Ultra High Performance Liquid Chromatography-Mass Spectrometry (UHPLC-MS) 74 
analysis. UHPLC-MS analysis of amniotic fluid extracts and QC samples was performed 75 
applying a Dionex U3000 coupled to an electrospray LTQ-FT-MS Ultra mass spectrometer 76 
(Thermo Scientific Ltd. UK). Samples were reconstituted in 100µL of 50:50 methanol:water, 77 
vortex-mixed for 15 seconds, centrifuged (15 minutes, 13,000 g) and transferred to vials 78 
with 200µL fixed inserts (Thermo-Fisher Ltd. U.K.). All samples were stored in the 79 
autosampler at 5°C and analysed separately in negat ive and positive electrospray 80 
ionisation (ESI) modes within 72 h of reconstitution. UHPLC separations were performed 81 
applying a Hypersil Gold C18 reversed phase column (100 x 2.1mm, 1.9µm) at a flow rate of 82 
400µL.min-1, column temperature of 40°C and with two solvents:  solvent A (HPLC grade 83 
water + 0.1% formic acid) and solvent B (HPLC grade methanol + 0.1% formic acid). A 84 
gradient elution was performed as follows: hold 100% A 0-1.5 min, 100% A - 100% B 1.5-6 85 
min curve 3, hold 100% B 6-12 min, 100% B – 100% A 12-13 min curve 3, hold 100% A 13-86 
15 min. Injection volume was 5µL. UHPLC eluent was introduced directly in to the 87 
electrospray LTQ-FT Ultra mass spectrometer with source conditions as follows: spray 88 
voltage -4.5 kV (ESI-) and +5 kV (ESI+), sheath gas 30 arbitrary units, aux gas 15 arbitrary 89 
units, capillary voltage 35 V, tube lens voltage -100 V (ESI-) and +90 V (ESI+), capillary 90 
temperature 280°C, ESI heater temperature 300°C. Da ta were acquired in the FT mass 91 
spectrometer in the m/z range 100-1000 at a mass resolution of 50,000 (FWHM defined at 92 
m/z 400), with a scan speed of 0.4 sec and an AGC setting of 1x106. Analysis order was 93 
composed of 10 QC sample injections for system conditioning followed by a QC sample 94 
injection every 6th injection with two QC sample injections at the end of the analytical run. 95 
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Amniotic fluid extracts for each subject were analysed in a random order; the two samples 96 
for each subject were analysed sequentially.  97 
Data pre-processing. UHPLC-MS raw data profiles were first converted into a NetCDF 98 
format within the Xcalibur software's File Converter program. Each NetCDF based three-99 
dimensional data matrix (intensity × m/z × retention time – one per sample) was converted 100 
into a vector of peak responses, using the freely available XCMS software as described 101 
previously (33). Data were exported from XCMS as a .csv file for further data analysis. 102 
Metabolite annotation was performed applying the PUTMEDID_LCMS workflow as 103 
previously described (34). All metabolite annotations are reported at level 2 (putatively 104 
annotated compounds) according to MSI reporting standards (35). In cases where a single 105 
metabolite is detected as multiple metabolite features (as described previously (36), only a 106 
single feature is reported chosen as having a p-value nearest to 0.05).  107 
Univariate and multivariate analysis. Intergroup comparisons for continuous variables 108 
with a non-parametric distribution were made using the Mann-Whitney U test to determine 109 
significant differences between the data sets. Median values and 95% confidence intervals 110 
(CI) are described. Categorical data were analysed using Fisher's exact test and odds 111 
ratios (OR) and 95%CI. Significance was taken as p<0.05. Metabolomics processed data 112 
were analysed in ‘R’ applying the unsupervised multivariate principal components analysis 113 
(PCA), supervised multivariate Partial Least Squares-Discriminant Analysis (PLS-DA), 114 
univariate non-parametric Wilcoxon Signed Rank test and Spearman rank correlation 115 
analysis. The fold change (median peak area before treatment/median peak area after 116 
treatment) was calculated including 95%CI. Metabolites were manually clustered into 117 
classes defining similar chemical structure or metabolic pathway to identify biologically 118 
relevant and robust metabolic changes.  119 
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Results 120 
Cohort of monochorionic twins complicated by TTTS and the effects of treatment 121 
Table 1 summarises the baseline demographic data of the whole cohort (n=19) at 122 
the time of diagnosis. In the total cohort of MCDA twins complicated by TTTS, 5.2% (1/19) 123 
had Quintero Stage-I, 15.8% (3/19) Stage-II, and 79% (15/19) Stage-III disease. The 124 
measured RV and LV MPI was elevated (>95%CI for gestation) in 89.4% (17/19) and 125 
73.7% (14/19) of recipients, respectively (Figure 1a and b). Of the two cases which had a 126 
RV MPI within 95%CI for gestation, one twin set had Quintero stage-I and one Quintero 127 
stage-III. In the 5 recipient fetuses with LV MPI within 95%CI, all had Quintero stage >II. In 128 
the recipient twin, additional features of cardiac dysfunction are described in Table 1. 129 
 FLC was performed at a median gestation of 20 weeks and 2 days (142 days) 130 
(95%CI 137.7 – 148.3). Recipient RV MPI (p=0.02) and LV MPI (p=0.03) decreased 131 
significantly after FLC (Figure 2a and b).  132 
Amniotic fluid metabolome of the recipient amniotic fluid 133 
38 paired amniotic fluid samples were collected before and after FLC. Following 134 
quality assurance of the data, 2694 and 1510 metabolite features remained in positive and 135 
negative ion modes, respectively.  136 
 137 
Correlation analysis of metabolic profiles and recipient cardiac function in TTTS 138 
Spearman rank correlation analysis was performed to identify associations between 139 
recipient RV and LV MPI at the time of diagnosis, and the concentration of each metabolite. 140 
A summary of the results demonstrating associations between recipient RV or LV MPI and 141 
amniotic fluid metabolites are shown in Table 2 and the full data are shown in 142 
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Supplementary Tables 2 and 3. The 118 and 102 metabolites identified as having an 143 
association with LV MPI or RV MPI each showed a positive correlation (denoted as ‘+’ 144 
showing that as LV MPI or RV MPI increase so does the metabolite concentration) or a 145 
negative correlation (denoted as ‘-‘ showing that as LV MPI or RV MPI increase the 146 
metabolite concentration decreases). 15 metabolites showed an association with LV MPI 147 
and RV MPI. Acyl carnitines, acyl glycerides, fatty acids and oxidised fatty acids were all 148 
negatively correlated with cardiac function whereas carbohydrates were positively 149 
correlated with cardiac function. Ceramides, sphingolipids and glycerophospholipids were 150 
also negatively correlated with cardiac function and may be related to changes in cell 151 
membranes. Hormones were negatively correlated with cardiac function. Finally, for LV 152 
MPI, two oxidative phosphorylation metabolites were negatively correlated with cardiac 153 
function but no metabolites were correlated with the RV MPI data.  154 
 155 
Comparison of metabolic changes before and after laser treatment independent of 156 
type of laser treatment 157 
200 metabolites showed a statistically significant change (p<0.005) in relative 158 
concentrations when comparing amniotic fluid samples taken before laser, and after laser 159 
treatment; this was unaffected by whether or not the Solomon technique was applied. 160 
Supplementary Table 1 lists the significantly altered metabolomic profiles (all metabolites 161 
are grouped into classes of chemical structure or metabolic pathway). Figure 3 162 
demonstrates these data as a “heat map” of relative concentration changes for all 163 
metabolite classes containing three or more metabolites. There were 13 metabolite 164 
“classes” consisting of ≥3 metabolites which demonstrated significant fold changes. These 165 
include acyl carnitines, acyl glycerides, amino acid metabolism, carbohydrate metabolism, 166 
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cholesterol esters, ceramides and sphingolipids, fatty acid metabolism, 167 
glycerophospholipids, haem metabolism, nucleosides, oxidised fatty acids, oxidative 168 
phosphorylation (electron transport chain) and thyroid/steroid hormone metabolism. These 169 
suggest a change in fetal or placental energy metabolism, specifically between 170 
carbohydrates (shown by higher levels of carbohydrates before treatment) and fatty acids 171 
(shown by higher levels of acyl carnitines, acyl glycerides, fatty acids, oxidised fatty acids 172 
and TCA/oxidative phosphorylation metabolites) in amniotic fluid post-FLC. Amniotic fluid 173 
oxidised fatty acid concentration shows a 50-fold change (higher concentration post-FLC). 174 
This is potentially a prostaglandin derivative known to have vasodilatory roles within the 175 
endothelium (37). Of five acyl carnitines, it is the medium chain derivatives (hexanoyl, 176 
octanoyl and decanoyl) that predominate. Also changes related to oxidative 177 
phosphorylation were noted (Supplementary Table 1). Concentrations of thyroid and steroid 178 
hormones were decreased post-FLC potentially related to an attenuated “stress” response 179 
post-FLC treatment.  180 
These observed changes may be secondary to placental destruction caused by 181 
coagulation (38), changes in recipient cardiovascular function post-laser coagulation or a 182 
combination of these events. Finally, uridine/pseudouridine was observed to be 20% higher 183 
before treatment and these metabolites have been observed to be increased in heart failure 184 
in adults (39). 185 
 186 
Discussion 187 
This cohort study demonstrates that the metabolomic profile in the amniotic fluid of 188 
recipient monochorionic twins complicated by TTTS is different when there is significant 189 
cardiac dysfunction, and that amniotic fluid metabolic profiles change in response to FLC. 190 
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Following FLC treatment, a wide range of different metabolite classes are perturbed in 191 
amniotic fluid in the recipient sac. The balance between carbohydrates and fatty acid for 192 
energy production appears to change following treatment to be preferential for fatty acids. 193 
The balance between carbohydrate and fatty acid metabolism appears to be related to 194 
recipient cardiac function (as measured by LV and RV MPI) as fatty acids are negatively 195 
correlated and carbohydrates are positively correlated with cardiac function. However, it is 196 
difficult to delineate whether the source of the metabolites is fetal or placental, as amniotic 197 
fluid is a composite of placental metabolite secretion and fetal metabolite secretion (e.g. as 198 
urine). As amniotic fluid sampling was repeated after a median time of 34 minutes, it is 199 
more probable that these changes are secondary to a combination of trophoblast/vessel 200 
destruction (as previously noted by an elevation in alpha-fetoprotein and human chorionic 201 
gonadatrophin) (38) and fetal cardiovascular change. 202 
In this relatively small cohort study a significant proportion of the recipient fetuses 203 
had evidence of cardiac dysfunction and an elevated LV and RV MPI. Such data are 204 
consistent with those previously described in the literature (3) and that recipient RV and LV 205 
MPI rapidly alters post-FLC (40). Much of the recipient cardiac effects are due to RV and LV 206 
diastolic dysfunction or hypertension (3). 207 
In adults with cardiac failure, prediction of survival is optimal when cardiac ultrasound 208 
measurements are combined with serum-derived biomarkers (41). Classically, the 209 
combination of cardiac Troponin T, atrial natriuretic polypeptide (ANP) and BNP is used as 210 
a marker to reflect cardiac dysfunction and a combination is better than one peptide alone. 211 
In recent years there has been a move to a metabolomic approach for profiling functional 212 
and metabolic changes in adults with heart failure (21).  213 
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In the fetal setting, determination of these peptides within fetal plasma would require 214 
fetal blood sampling which would carry significant procedure-related complications. 215 
However, therapy for TTTS by FLC involves the removal of redundant amniotic fluid from 216 
the recipient’s sac after completion of the procedure. At this gestation, amniotic fluid is 217 
composed mainly of fetal urine and is therefore a potential source for fetal cardiac 218 
biomarkers. The presence of cardiac Troponin T in amniotic fluid has previously been 219 
described in severely growth restricted fetuses (42) and also in recipient fetuses with fetal 220 
cardiac dysfunction in TTTS (3). Also, in pregnancies complicated by TTTS, ANP and brain-221 
type natriuretic peptide (BNP) have been identified in the amniotic fluid (4, 43) and have 222 
also been noted to be associated with fetal recipient cardiac dysfunction in TTTS (3).  223 
15 metabolites in the amniotic fluid of the recipient sac prior to laser coagulation 224 
demonstrated an association with LV MPI and RV MPI. Acyl carnitines, acyl glycerides, fatty 225 
acids and oxidised fatty acids were all negatively correlated with cardiac function whereas 226 
carbohydrates were positively correlated with cardiac function. This implies that the balance 227 
between using carbohydrates and fatty acids as substrates for energy metabolism has an 228 
influence on fetal cardiac function, though causality still requires testing. This balance has 229 
been shown to be important in cardiac diseases including hypertrophic cardiomyopathy 230 
(44). Ceramides, sphingolipids and glycerophospholipids were also negatively correlated 231 
with cardiac function and may be related to changes in cell membranes. Hormones were 232 
negatively correlated with cardiac function. Finally, for LV MPI, two oxidative 233 
phosphorylation metabolites were negatively correlated with cardiac function but no 234 
metabolites were for the RV MPI data. Of interest and worthy of further study also are the 235 
changes in N,N-dimethylarginine and the structurally similar N,N-diacetylspermine. N,N-236 
dimethylarginine is a known inhibitor of NO synthesis from arginine and therefore reduces 237 
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vasodilation. Symmetrical and asymmetrical N,N-dimethylarginine are implicated in cardiac 238 
function and cardiovascular health (45, 46). 239 
There were also 13 metabolite “classes” consisting of ≥3 metabolites which 240 
demonstrated significant fold changes in amniotic fluid after FLC. These include acyl 241 
carnitines, acyl glycerides, amino acid metabolism, carbohydrate metabolism, cholesterol 242 
esters, ceramides and sphingolipids, fatty acid metabolism, glycerophospholipids, haem 243 
metabolism, nucleosides, oxidised fatty acids, oxidative phosphorylation (electron transport 244 
chain) and thyroid/steroid hormone metabolism. These suggest a change in fetal or 245 
placental energy metabolism, specifically between carbohydrates (shown by higher levels of 246 
carbohydrates before treatment) and fatty acids (shown by higher levels of acyl carnitines, 247 
acyl glycerides, fatty acids, oxidised fatty acids and TCA/oxidative phosphorylation 248 
metabolites) in amniotic fluid post-FLC. Similar changes in the balance of carbohydrate and 249 
fatty acid usage for energy production in hypertrophic cardiomyopathy have been 250 
previously reported (44). In TTTS, amniotic fluid levels of BNP appear to correlate with the 251 
severity of recipient cardiac dysfunction (3). The higher levels of fatty acids and lower levels 252 
of carbohydrates post-FLC suggest that there is a switch from fetal or placental use of fatty 253 
acids as precursors for energy metabolism to carbohydrates. 254 
Amniotic fluid oxidised fatty acid concentration shows a 50-fold change (higher 255 
concentration post-FLC). This is potentially a prostaglandin derivative known to have 256 
vasodilatory roles within the endothelium (37). Of five acyl carnitines, it is the medium chain 257 
derivatives (hexanoyl, octanoyl and decanoyl) that predominated suggesting a specific 258 
perturbation in medium chain fatty acid oxidation. 259 
Two published studies (from the same group) in singleton pregnancies (47, 48) have 260 
investigated the amniotic fluid metabolome. These data noted 70 metabolomic compounds 261 
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using (1)H NMR. Pregnancies complicated by a heterogeneous group of fetal 262 
malformations demonstrated “variations in glucose, some amino acids and organic acids 263 
and proteins”.  However, it is recognised that this group is heterogeneous for malformations 264 
and thus it was difficult to draw conclusions. The amniotic fluid samples were taken by 265 
amniocentesis at a wide gestational range (13 – 42 weeks) in these singleton pregnancies. 266 
Subjects with gestational diabetes showed an average increase in glucose and small 267 
decreases in several amino acids along with acetate, formate, creatinine, and 268 
glycerophosphocholine. Small metabolite changes were also observed in the amniotic fluid 269 
of singleton pregnancies which eventually underwent preterm delivery and premature 270 
rupture of membranes.  It is difficult to draw comparisons to our cohort, as these 271 
pregnancies have taken amniotic fluid from a recipient sac in complex monochorionic 272 
multiple pregnancies (in a narrow gestational age range). 273 
This is the first study of energy metabolism in TTTS and FLC. We have reported the 274 
correlation of the balance between fatty acid and carbohydrate use in energy metabolism 275 
and their associations with measures of global recipient cardiac dysfunction and the effects 276 
of laser ablative treatment. Additional research is required to delineate the origin of these 277 
metabolomic changes, although it would be difficult to obtain ethical approval to perform 278 
repeat amniocenteses in these high-risk pregnancies which we would enable us to explore 279 
these changes. Further targeted metabolomics studies in different biofluids and tissues are 280 
now required to identify potential prognostic ‘biomarkers’ to improve outcome in 281 
monochorionic twin pregnancies complicated by TTTS. 282 
 283 
Contributors: WBD and JWA analysed samples, interpreted data and wrote manuscript. 284 
TVM helped with calculation of the MPI and normalising these data as gestationally related 285 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
13 
 
 
 
z-scores, as well as contributing to writing the manuscript. RKM, FLM, and CEF helped with 286 
procedures, collecting samples, interpreting results and writing manuscript. MDK performed 287 
the procedures, interpreted the results and wrote the manuscript. MDK conceived idea. All 288 
authors contributed to writing the manuscript and have seen and approved the final version.  289 
 290 
Acknowledgements: JWA and WD wish to acknowledge the Systems Science for Health 291 
Initiative at the University of Birmingham for financial support. This work was supported by 292 
Wellbeing of Women (through an Entry Level Scholarship to CEF) and the Wiseman Trust 293 
(supporting FLM). 294 
 295 
 296 
 297 
 298 
299 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
14 
 
 
 
References 300 
1. Van Mieghem T, Klaritsch P, Done E, Gucciardo L, Lewi P, Verhaeghe J, et al. Assessment of fetal 301 
cardiac function before and after therapy for twin-to-twin transfusion syndrome. American Journal of 302 
Obstetrics & Gynecology. 2009;200(4):400.e1-7. 303 
2. Kilby M, Platt C, Whittle M, Oxley J, Lindop G. Renin-gene expression in fetal kidneys of pregnancies 304 
complicated by twin-twin transfusion syndrome. Pediatr Dev Pathol. 2001;4:175-9. 305 
3. Van Mieghem T, Doné E, Gucciardo L, Klaritsch P, Allegaert K, Van Bree R, et al. Amniotic fluid 306 
markers of fetal cardiac dysfunction in twin-to-twin transfusion syndrome. Am J Obstet Gynecol. 307 
2010;202(1):48.e1-.e7. 308 
4. Bajoria R, Ward S, Chatterjee R. Brain natriuretic peptide and endothelin-1 in the pathogenesis of 309 
polyhydramnios-oligohydramnios in monochorionic twins. American Journal of Obstetrics & Gynecology. 310 
2003;189(1):189-94. 311 
5. Lewi L, Jani J, Blickstein I, Huber A, Gucciardo L, Van Mieghem T, et al. The outcome of 312 
monochorionic diamniotic twin gestations in the era of invasive fetal therapy: a prospective cohort study. 313 
Am J Obstet Gynecol. 2008;199(5):514.e1-.e8. 314 
6. Roberts D, Neilson J, Kilby M, Gates S. Interventions for the treatment of twin-twin transfusion 315 
syndrome. Cochrane Database Syst Rev. 2014. 316 
7. Lenclen R, Ciarlo G, Paupe A, Bussieres L, Ville Y. Neurodevelopmental outcome at 2 years in children 317 
born preterm treated by amnioreduction or fetoscopic laser surgery for twin-to-twin transfusion syndrome: 318 
comparison with dichorionic twins. . Am J Obstet Gynecol. 2009;201(3):e1-5. 319 
8. Habli M, Livingston J, Harmon J, Lim FY, Plozin W, Crombleholme T. The outcome of twin–twin 320 
transfusion syndrome complicated with placental insufficiency. Am J Obstet Gynecol. 2008;199(4):424.e1-321 
.e6. 322 
9. Eschbach S, Boons L, Wolterbeek R, Middeldorp J, Klumper F, Lopriore E, et al. Prediction of single 323 
fetal demise after laser therapy for twin-to-twin transfusion syndrome. Ultrasound Obstet Gynecol. 324 
2015:epub ahead of print. 325 
10. Dunn W, Broadhurst D, Atherton H, Goodacre R, Griffin J. Systems level studies of mammalian 326 
metabolomes: the roles of mass spectrometry and nuclear magnetic resonance spectroscopy. Chem Soc Rev. 327 
2011;40(1):387-426. 328 
11. Cosmi E, Visentin S, Favretto D, Tucci M, Ragazzi E, Viel G, et al. Selective intrauterine growth 329 
restriction in monochorionic twin pregnancies: Markers of endothelial damage and metabolomic profile. 330 
Twin Research and Human Genetics. 2013;16(4):816-26. 331 
12. Diaz S, Barros A, Goodfellow B, Duarte I, Galhano E, Pita C, et al. Second trimester maternal urine for 332 
the diagnosis of trisomy 21 and prediction of poor pregnancy outcomes. J Proteome Res. 2013;12(6):2946-333 
57. 334 
13. Horgan R, Broadhurst D, Dunn W, Brown M, Heazell A, Kell D, et al. Changes in the metabolic 335 
footprint of placental explant-conditioned medium cultured in different oxygen tensions from placentas of 336 
small for gestational age and normal pregnancies. Placenta. 2010;31(10):893-901. 337 
14. Stevens A, Bonshek C, Whatmore A, Butcher I, Hanson D, De Leonibus C, et al. Insights into the 338 
pathophysiology of catch-up compared with non-catch-up growth in children born small for gestational age: 339 
an integrated analysis of metabolic and transcriptomic data. Pharmacogenomics. 2014;14(4):376-84. 340 
15. Bahado-Singh R, Syngelaki A, Akolekar R, Mandal R, Bjondahl T, Han B, et al. Validation of 341 
metabolomic models for prediction of early-onset preeclampsia. Am J Obstet Gynecol. 2015;213(4):530.e1-342 
e.10. 343 
16. Kenny L, Broadhurst D, Dunn W, Brown M, North R, McCowan L, et al. Robust early pregnancy 344 
prediction of later preeclampsia using metabolomic biomarkers. Hypertension. 2010;56(4):741-9. 345 
17. Dunn W, Brown M, Worton S, Crocker I, Broadhurst D, Horgan R, et al. Changes in the metabolic 346 
footprint of placental explant-conditioned culture medium identifies metabolic disturbances related to 347 
hypoxia and pre-eclampsia. Placenta. 2009;30(11):974-80. 348 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
15 
 
 
 
18. Lehmann R, Friedrich T, Krebiehl G, Sonntag D, Häring H, Fritsche A, et al. Metabolic profiles during 349 
an oral glucose tolerance test in pregnant women with and without gestational diabetes. Exp Clin Endocrinol 350 
Diabetes. 2015;123(7):483-38. 351 
19. Dani C, Bresci C, Berti E, Ottanelli S, Mello G, Mecacci F, et al. Metabolomic profile of term infants of 352 
gestational diabetic mothers. J Matern Fetal Neonatal Med. 2014;27(6):537-42. 353 
20. Wang T, Gupta D. Metabolite profiles in heart failure: looking for unique signatures in a 354 
heterogeneous syndrome. J Am Coll Cardiol. 2015;65(15):1521-4. 355 
21. Deidda M, Piras C, Dessalvi C, Locci E, Barberini L, Torri F, et al. Metabolomic approach to profile 356 
functional and metabolic changes in heart failure. J Transl Med. 2015;13:297. 357 
22. Gussi I, Nizard J, Yamamoto M, Robyr R, Ville Y. Maternal pseudo primary hyperaldosteronism in 358 
twin-to-twin transfusion syndrome. Br J Obstet Gynaecol. 2007;114(1):65-9. 359 
23. Adama van Scheltema P, In't Anker P, Vereecken A, Vandenbussche F, Kanhai H, Devlieger R. 360 
Biochemical composition of amniotic fluid in pregnancies complicated with twin-twin transfusion syndrome. 361 
Fetal Diagn Ther. 2005;2005(20):3. 362 
24. Fox CE, Lash GE, Pretlove SJ, Chan BC, Holder R, Kilby MD. Maternal plasma and amniotic fluid 363 
angiogenic factors and their receptors in monochorionic twin pregnancies complicated by twin-to-twin 364 
transfusion syndrome. Ultrasound in obstetrics & gynecology : the official journal of the International Society 365 
of Ultrasound in Obstetrics and Gynecology. 2010;35(6):695-701. 366 
25. Fox CE, Lash GE, Pretlove SJ, Chan BC, Holder R, Kilby MD. Maternal plasma and amniotic fluid 367 
cytokines in monochorionic, diamniotic twin pregnancies complicated by twin-to-twin transfusion syndrome. 368 
Fetal Diagnosis and Therapy. 2014;35(4):280-8. 369 
26. Hui L, Wick H, Moise KJ, Johnson A, Luks F, Haeri S, et al. Global gene expression analysis of amniotic 370 
fluid cell-free RNA from recipient twins with twin-twin transfusion syndrome. Prenat Diagn. 2013;33(9):873-371 
83. 372 
27. Bahado-Singh R, Ertl R, Mandal R, Bjorndahl T, Syngelaki A, Han B, et al. Metabolomic prediction of 373 
fetal congenital heart defect in the first trimester. Am J Obstet Gynecol. 2014;211(3):241. 374 
28. Quintero R, Morales W, Allen M, Bornick O, Johnson P, Kruger M. Staging of twin-twin transfusion 375 
syndrome. J Perinatol. 1999;19:550-5. 376 
29. Tsutsumi T, Ishii M, Eto G, Hota M, Kato H. Serial evaluation for myocardial performance in fetuses 377 
and neonates using a new Doppler index. Pediatr Int. 1999;41(6):722-7. 378 
30. Morris RK, Selman TJ, Harbidge A, Martin WL, Kilby MD. Fetoscopic laser coagulation for severe twin-379 
to-twin transfusion syndrome: factors influencing perinatal outcome, learning curve of the procedure and 380 
lessons for new centres. BJOG. 2010;117(11):1350-7. 381 
31. Slaghekke F, Lopriore E, Lewi L, Middeldorp J, van Zwet E, Weingertner A-S, et al. Fetoscopic laser 382 
coagulation of the vascular equator versus selective coagulation for twin-to-twin transfusion syndrome: an 383 
open-label randomised controlled trial. The Lancet. 2014;383(9935):2144-51. 384 
32. Dunn W, Broadhurst D, Begley P, Zelena E, Francis-McIntyre S, Anderson N, et al. Procedures for 385 
large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography 386 
coupled to mass spectrometry. Nat Protoc. 2011;6(7):1060-83. 387 
33. Dunn W, Broadhurst D, Brown M, Baker P, Redman C, Kenny L, et al. Metabolic profiling of serum 388 
using Ultra Performance Liquid Chromatography and the LTQ-Orbitrap mass spectrometry system. J 389 
Chromatogr B Analyt Technol Biomed Life Sci. 2008;871(2):288-98. 390 
34. Brown M, Wedge D, Goodacre R, Kell D, Baker P, Kenny L, et al. Automated workflows for accurate 391 
mass-based putative metabolite identification in LC/MS-derived metabolomic datasets. Bioinformatics. 392 
2011;27(8):1108-12. 393 
35. Sumner L, Amberg A, Barrett D, Beale M, Beger R, Daykin C, et al. Proposed minimum reporting 394 
standards for chemical analysis Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative 395 
(MSI). Metabolomics. 2007;3(3):211-21. 396 
36. Brown M, Dunn WB, Dobson P, Patel Y, Winder CL, Francis-McIntyre S, et al. Mass spectrometry 397 
tools and metabolite-specific databases for molecular identification in metabolomics. Analyst. 398 
2009;134:1322. 399 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
16 
 
 
 
37. Durand M, Gutterman D. Diversity in mechanisms of endothelium-dependent vasodilation in health 400 
and disease. Microcirculation. 2013;20(3):239-47. 401 
38. Fox CE, Pretlove SJ, Chan BC, Mahony RT, Holder R, Kilby MD. Maternal serum markers of placental 402 
damage in uncomplicated dichorionic and monochorionic pregnancies in comparison with monochorionic 403 
pregnancies complicated by severe twin-to-twin transfusion syndrome and the response to fetoscopic laser 404 
ablation. Eur J Obstet Gynecol Reprod Biol. 2009;144(2):124-9. 405 
39. Dunn WB, Broadhurst DI, Deepak SM, Mamta B, M.H, McDowell G, Spasic I, et al. Serum 406 
metabolomics reveals many novel metabolic markers of heart failure, including pseudouridine and 2-407 
oxoglutarate. Metabolomics. 2007;3(413). 408 
40. Papanna R, Mann L, Molina S, Johnson A, Moise K. Changes in the recipient fetal Tei index in the 409 
peri-operative period after laser photocoagulation of placental anastomoses for twin-twin transfusion 410 
syndrome. Prenat Diagn. 2011;31(2):176-80. 411 
41. Latini R, Masson S, Anand IS, Missov E, Carlson M, Vago T, et al. Prognostic value of very low plasma 412 
concentrations of troponin T in patients with stable chronic heart failure. Circulation. 2007;116(11):1242-9. 413 
42. Stefanovic V, Loukovaara M. Amniotic fluid cardiac troponin T in pathological pregnancies with 414 
evidence of chronic fetal hypoxia. Croat Med J. 2005;46(5):801-7. 415 
43. Bajoria R, Ward S, Sooranna SR. Atrial natriuretic peptide mediated polyuria: pathogenesis of 416 
polyhydramnios in the recipient twin of twin-twin transfusion syndrome. Placenta. 2001;22(8-9):716-24. 417 
44. Abozguia K, Elliott P, McKenna W, Phan T, Nallur-Shivu G, Ahmed I, et al. Metabolic modulator 418 
perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic 419 
cardiomyopathy. Circulation. 2010;122(16):1562-9. 420 
45. Gore M, Lüneburg N, Schwedhelm E, Ayers C, Anderssohn M, Khera A, et al. Symmetrical 421 
dimethylarginine predicts mortality in the general population: observations from the Dallas heart study. 422 
Arterioscler Thromb Vasc Biol. 2013;33(11):2682-8. 423 
46. Gorenflo M, Zheng C, Werle E, Fiehn W, Ulmer H. Plasma levels of asymmetrical dimethyl-L-arginine 424 
in patients with congenital heart disease and pulmonary hypertension. J Cardiovasc. 2001;Pharmacol(37):4. 425 
47. Graça G, Duarte IF, Barros AS, Goodfellow BJ, Diaz S, Carreira IM, et al. 1H NMR based 426 
metabonomics of human amniotic fluid for the metabolic characterization of fetus malformations. J 427 
Proteome Res. 2009;8(8):4144-50. 428 
48. Graça G, Duarte IF, Barros AS, Goodfellow BJ, Diaz SO, Pinto J, et al. Impact of prenatal disorders on 429 
the metabolic profile of second trimester amniotic fluid: a nuclear magnetic resonance metabonomic study. J 430 
Proteome Res. 2010;9(11):6016-24. 431 
 432 
Tables and Figures Legend 433 
Table 1: Demographic and clinical data for all participating subjects (n=19 twin 434 
pregnancies; n=38 fetuses) 435 
Table 2: Correlation of metabolic profiles and cardiac function (Left Ventricle (LV) 436 
and Right Ventricle (RV) Myocardial Performance Index (MPI)) according to 437 
metabolite class 438 
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Figure 1: (a) Right ventricular myocardial performance index (RV-MPI) (b) Left 439 
ventricular myocardial performance index (LV-MPI) in recipient fetuses 440 
The graph demonstrates individual fetal values against gestational age (and with reference 441 
to the 95%CI). 442 
Figure 2: Changes in: a) Right Ventricular Myocardial Performance Index (RVMPI) 443 
and b) Left Ventricular Myocardial Performance Index (LVMPI) after pre- and post- 444 
fetoscopic laser coagulation in recipient twins 445 
RV and LV MPI z-scores before and immediately post- fetoscopic laser coagulation 446 
(individual data shown). 447 
Figure 3: Heat map showing the distribution of concentrations for individual 448 
metabolites (rows) for samples collected before and after fetoscopic laser 449 
coagulation (columns). Green shows a low concentration whereas red shows a high 450 
concentration in the range of concentrations for each metabolite. Abbreviations are amino 451 
acid metabolism (AA), acyl carnitines (AC), acyl glycerides (AG), carbohydrates (C), 452 
cholesterol esters (CE), ceramides and sphingolipids (CS), fatty acids (FA), 453 
glycerophospholipids (GPL), haem metabolism (H), nucleotides (N), oxidised fatty acids 454 
(OFA), oxidative phosphorylation (OP) and thyroid/steroid hormones (TSH).  455 
 456 
Supplementary Tables 457 
Supplementary Table 1: Metabolites showing a statistically significant (p<0.005) 458 
change in relative metabolite concentrations before and after fetoscopic laser 459 
coagulation. All metabolites are grouped into classes of chemical structure or metabolic 460 
pathway. Fold change is calculated as the median (before treatment)/median (after 461 
treatment) and the 95% confidence intervals are included in brackets. 462 
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Supplementary Table 2: Metabolites showing an association between their 463 
concentration and the Right Ventricle Myocardial Performance Index (MPI) at 464 
diagnosis and before fetoscopic laser coagulation. All metabolites listed demonstrated 465 
a Spearman Rank correlation between -1.0 to -0.3 or +0.3 to +1.0 and are grouped into 466 
classes of chemical structure or metabolic pathway. 467 
Supplementary Table 3: Metabolites showing an association between their 468 
concentration and the Left Ventricle Myocardial Performance Index (MPI) at 469 
diagnosis and before fetoscopic laser coagulation. All metabolites listed demonstrated 470 
a Spearman Rank correlation between -1.0 to -0.3 or +0.3 to +1.0 and are grouped into 471 
classes of chemical structure or metabolic pathway. 472 
 473 
474 
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Table 1: Demographic and clinical data for all participating subjects (n=19 twin 475 
pregnancies; n=38 fetuses) 476 
Patient characteristics Median (95%CI) 
Maternal age (years) 29 (26.1 – 31.3) 
Maternal BMI 24 (22.8 – 27.7) 
Gestational age at diagnosis and FLC (days) 142 (137.7 – 148.3) 
% difference in EFW 25.2 (21.9 – 31.9) 
Recipient fetal cardiac measurements  
Recipient RV MPI (z-score) Median (95%CI) 4.96 (3.62 – 5.50) 
Recipient absent/reversed “A-wave” in Ductus Venosus 
n (%) 
7/19 (36.8) 
Recipient tricuspid regurgitation n (%) 15/19 (78.9) 
Recipient RV E/A ratio > 95%CI for gestation n (%) 11/19 (57.9) 
Recipient LV MPI (z-score) Median (95%CI) 2.71 (2.07 – 3.63) 
Fetoscopic laser coagulation (FLC) variables  
Duration of FLC and amniodrainage (minutes) Median 
(range) 
34 (21 - 45) 
Duration of FLC (minutes) Median (range) 19 (9 – 28) 
Number of arteriovenous anastomoses coagulated 
Median (95%CI) 
8 (7.4 – 8.3) 
Amniodrainage post-laser coagulation (ml) Median 
(95%CI) 
2600 (1800 – 4000) 
Pregnancy outcomes  
Gestational age at delivery (days) Median (95%CI) 227 (207.1 – 232.7) 
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Perinatal survival of all fetuses* (at 28 days) n (%) 30/38 (78.9) 
At least one survivor in pregnancy n (%) 18/19 (94.7) 
Two survivors n (%) 12/19 (63.2) 
One survivor n (%) 6/19 (31.5) 
No survivors n (%) 1/19 (5.3) 
 477 
Key: BMI: body mass index, EFW: estimated fetal weight, MPI: myocardial performance 478 
index, RV: right ventricle.  479 
(†Intergroup comparisons for continuous variables with a non-parametric distribution were 480 
made using the Mann-Whitney U test to determine significant differences between the data 481 
sets. For such data, median values and 95%CI are described. Categorical data were 482 
analysed using Fisher's exact test and relative risk ratios and 95% confidence intervals. 483 
Significance was taken as P<0.05 unless otherwise stated) 484 
*Perinatal mortality defined as total number of survivors (all fetuses) who survived until at 485 
least 28 days of age. 486 
 487 
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Table 2: Correlation of metabolic profiles and cardiac function (Left Ventricle (LV) and Right Ventricle (RV) Myocardial 
Performance Index (MPI)) according to metabolite class 
Metabolite Class Left Ventricle (LV) MPI Right Ventricle (RV) MPI 
Number of 
Metabolites 
Correlation 
coefficient range 
Number of 
Metabolites 
Correlation 
coefficient range 
Acyl amino acids 2 +0.34 to +0.39 2 +0.30 to +0.37 
Acyl carnitine 5 -0.46 to +0.41 6 -0.43 to -0.31 
Acyl glycerides 12 -0.52 to +0.54 9 -0.49 to +0.60 
Bile acid metabolism 3 -0.38 to +0.44 3 +0.31 to +0.36 
Carbohydrates 3 -0.57 to +0.65 4 -0.33 to +0.45 
Ceramides and sphingolipids 8 -0.43 to -0.30 9 -0.49 to +0.42 
CoA metabolism 2 -0.34 to +0.36 2 -0.40 to -0.30 
Fatty acid metabolism 10 -0.67 to +0.54 13 -0.52 to +0.46 
Glycerophospholipids 41 -0.53 to +0.50 28 -0.64 to +0.51 
Nucleoside 3 -0.48 to +0.34 4 -0.36 to +0.54 
Oxidised fatty acids 4 -0.31 to -0.30 7 -0.48 to +0.57 
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The metabolites identified as having an association with LV MPI or RV MPI (denoted as ‘+’ correlation coefficient shows that as LV 
MPI or RV MPI increase so does the metabolite concentration) or a negative correlation (denoted as ‘-‘ shows that as LV MPI or RV 
MPI increase the metabolite concentration decreases). 
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Figure 1: (a) Right ventricular myocardial performance index (RV-MPI) (b) Left 
ventricular myocardial performance index (LV-MPI) in recipient fetuses 
The graph demonstrates individual fetal values against gestational age (and with reference 
to the 95%CI). 
Figure 2: Changes in: a) Right Ventricular Myocardial Performance Index (RVMPI) 
and b) Left Ventricular Myocardial Performance Index (LVMPI) after pre- and post- 
fetoscopic laser coagulation in recipient twins 
RV and LV MPI z-scores before and immediately post- fetoscopic laser coagulation 
(individual data shown). 
Figure 3: Heat map showing the distribution of concentrations for individual 
metabolites (rows) for samples collected before and after fetoscopic laser 
coagulation (columns). Green shows a low concentration whereas red shows a high 
concentration in the range of concentrations for each metabolite. Abbreviations are amino 
acid metabolism (AA), acyl carnitines (AC), acyl glycerides (AG), carbohydrates (C), 
cholesterol esters (CE), ceramides and sphingolipids (CS), fatty acids (FA), 
glycerophospholipids (GPL), haem metabolism (H), nucleotides (N), oxidised fatty acids 
(OFA), oxidative phosphorylation (OP) and thyroid/steroid hormones (TSH).  
 
Supplementary Tables 
Supplementary Table 1: Metabolites showing a statistically significant (p<0.005) 
change in relative metabolite concentrations before and after fetoscopic laser 
coagulation. All metabolites are grouped into classes of chemical structure or metabolic 
pathway. Fold change is calculated as the median (before treatment)/median (after 
treatment) and the 95% confidence intervals are included in brackets. 
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Supplementary Table 2: Metabolites showing an association between their 
concentration and the Right Ventricle Myocardial Performance Index (MPI) at 
diagnosis and before fetoscopic laser coagulation. All metabolites listed demonstrated 
a Spearman Rank correlation between -1.0 to -0.3 or +0.3 to +1.0 and are grouped into 
classes of chemical structure or metabolic pathway. 
Supplementary Table 3: Metabolites showing an association between their 
concentration and the Left Ventricle Myocardial Performance Index (MPI) at 
diagnosis and before fetoscopic laser coagulation. All metabolites listed demonstrated 
a Spearman Rank correlation between -1.0 to -0.3 or +0.3 to +1.0 and are grouped into 
classes of chemical structure or metabolic pathway. 
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ventricular myocardial performance index (LV-MPI) in recipient fetuses 
The graph demonstrates individual fetal values against gestational age (and with 
reference to the 95%CI). 
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(RVMPI) and b) Left Ventricular Myocardial Performance Index (LVMPI) after 
pre- and post- fetoscopic laser coagulation in recipient twins 
RV and LV MPI z-scores before and 6 hours post- fetoscopic laser coagulation (individual 
data shown). 
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Highlights 
 
1. Metabolomic changes are seen after fetoscopic laser coagulation (FLC) 
2. Carbohydrate and fatty acid metabolism appears altered following FLC 
3. These findings are in keeping with changes seen in adults with cardiomyopathy 
4. Metabolomics may provide new biomarkers for twin twin transfusion syndrome 
